SKIP TO CONTENT
about abbott
contact
United States | eng
Country Language
CARDIOVASCULAR
United States | eng
Country Language

MOMENTUM 3 Trial

Publications and Presentations

Momentum 3 2-Year Outcomes – Full Cohort

MOMENTUM 3 2-Year Outcomes – Full Cohort

1028 Patients Followed for Two Years

Final Report of the Two-Year Principal Outcomes in the MOMENTUM 3 Full Cohort

 

Mehra, M.R., Uriel, N., Naka, Y., Cleveland, J.C., Yuzefpolskaya, M., …Goldstein, D.J., for the MOMENTUM 3 Investigators. (2019). A Fully Magnetically Levitated Left Ventricular Assist Device – Final Report. N Engl J Med. https://www.doi.org/10.1056/NEJMoa1900486

The data from two-year followup of the MOMENTUM 3 full cohort demonstrates:

  • Clinical superiority of the HeartMate 3 LVAS when compared to the HeartMate II LVAS
  • Significantly less frequent rate for pump replacement with HeartMate 3 LVAS
  • Significantly lower rate of stroke and disabling stroke with HeartMate 3 LVAS
  • Significantly lower rate of GI bleeding with HeartMate 3 LVAS
  • Significantly lower rate of pump thrombosis with HeartMate 3 LVAS
View Article
Download Presentation

Effect Of Aspirin Dose On Hemocompatibility-Related Outcomes

 

Saeed, O., Colombo, P.C., Mehra, M.R., ...Jorde, U.P. (2020). Effect of aspirin dose on hemocompatibility-related outcomes with a magnetically levitated left ventricular assist device: An analysis from the MOMENTUM 3 study. J Heart Lung Transplant. https://www.jhltonline.org/article/S1053-2498(20)31427-3/fulltext

This analysis of HM3-supported patients in the MOMENTUM 3 full cohort demonstrates:

  • Subjects receiving low-dose aspirin (81 mg) were more likely to be older and designated as destination therapy compared to subjects receiving usual-dose aspirin (325 mg)
  • A similar proportion of patients in the usual-and low-dose groups met the primary endpoint of hemocompatibility-related outcomes at 2 years
  • No differences in survival free from hemorrhagic or thrombotic events between the usual- and low-dose groups
View Article
Effect Of Aspirin Dose On Hemocompatibility-Related Outcomes

Infection-Related Outcomes

 

Patel., C.B., Blue, L., Cagliostro, B., ...Mehra, M.R. (2020). Left Ventricular Assist Systems and Infection-Related Outcomes: A Comprehensive Analysis of the MOMENTUM 3 Trial. J Heart Lung Transplant. https://www.jhltonline.org/article/S1053-2498(20)31428-5/fulltext

This analysis of the MOMENTUM 3 full cohort demonstrates:

  • Major infections occurred in over half of the subjects
  • The most common type of infection were those of a local nature and unrelated to pump components
  • Predictors of infection included female gender, pre-implant use of IABP, pre-implant history of cardiac surgery, and obesity.
View Article
Infection-Related Outcomes

Clinical Outcomes by Intended Goal of Therapy in the MOMENTUM 3 Full Cohort

 

Goldstein, D.J., Naka, Y., Horstmanshof, D., ...Mehra, M.R. (2019). Association of Clinical Outcomes with Left Ventricular Assist Device Use by Bridge to Transplant or Destination Therapy Intent: The Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Support Therapy with HeartMate 3 (MOMENTUM 3) Randomized Clinical Trial. JAMA Cardiology.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2758869

This analysis of the MOMENTUM 3 full cohort demonstrates the following:

  • Pre-implant strategy designations are dynamic and unpredictable
  • Adverse event profiles are similar for patients regardless of pre-implant strategy
  • Pre-implant strategy was not a determining factor in primary endpoint outcomes
View Article
Download Presentation
Clinical Outcomes by Intended Goal of Therapy in the MOMENTUM 3 Full Cohort

Hemocompatibility Related Outcomes at Two Years in the MOMENTUM 3 Full Cohort

 

Uriel, N., Mehra, M.R., Naka, Y., Boyle, A., …Cleveland, J.C., for the MOMENTUM 3 Investigators. (2019). Long-Term Burden of Hemocompatibility Related Adverse Events in the MOMENTUM 3 Trial: Final Analysis of the 1028 Patient Cohort. Presented at ISHLT 2019 Annual Meeting, Orlando, FL.

This analysis of the MOMENTUM 3 full cohort demonstrates the following:

  • The HeartMate 3 LVAS is clinically superior and more hemocompatible compared to the HeartMate II LVAS
  • HeartMate 3 patients experience an overall halving of the burden of hemocompatibility related adverse events compared to HeartMate II LVAS
Download Presentation
Hemocompatibility Related Outcomes at Two Years in the MOMENTUM 3 Full Cohort

HeartMate 3 Surgical Implant Technique and Outcomes in the MOMENTUM 3 Full Cohort

 

Salerno, C., Naka, Y., Silvestry, S.C., Goldstein, D.J., …Long, J.W., for the MOMENTUM 3 Investigators. (2019). HeartMate 3 Surgical Implant Technique and Outcomes in the MOMENTUM 3 Trial. Presented at ISHLT 2019 Annual Meeting, Orlando, FL.

This analysis of the MOMENTUM 3 full cohort demonstrates the following:

  • Apical cuff attachment, coring location, and driveline management did not significantly impact survival or key adverse events in the full cohort
  • Sew then Core was not associated with a lower stroke risk than Core then Sew
  • Similar excellent results can be obtained with HeartMate 3 LVAS despite significant variability in surgical implant techniques
Download Presentation
HeartMate 3 Surgical Implant Technique and Outcomes in the MOMENTUM 3 Full Cohort

HeartMate 3 LVAS Outflow Graft Twist Occlusion in the MOMENTUM 3 Full Cohort

 

Mehra, M.R., Salerno, C., Naka, Y., Uriel, N., Cleveland, J.C., Horstmanshof, D., and Goldstein, D.J., for the MOMENTUM 3 Investigators. (2018). A tale of the twist in the outflow graft: An analysis from the MOMENTUM 3 trial. J Heart Lung Transplant, 37 (11), 1281-4. https://www.jhltonline.org/article/S1053-2498(18)31615-2/fulltext

Reports have surfaced of a twist within the outflow graft of the HeartMate 3 LVAS, which have caused disruption in pump flow and required surgical correction. This article analyzes outflow graft twist occlusion in the MOMENTUM 3 trial experience and its clinical presentation.

View Article
HeartMate 3 LVAS Outflow Graft Twist Occlusion in the MOMENTUM 3 Full Cohort

MAT-2006845 v2.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
abbott logo

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2023 Abbott. All Rights Reserved.

MAT-1900882 v10.0